ES2557988T3 - Método para tratar enfermedades de próstata basado en el suministro local de principios activos - Google Patents

Método para tratar enfermedades de próstata basado en el suministro local de principios activos Download PDF

Info

Publication number
ES2557988T3
ES2557988T3 ES06724133.1T ES06724133T ES2557988T3 ES 2557988 T3 ES2557988 T3 ES 2557988T3 ES 06724133 T ES06724133 T ES 06724133T ES 2557988 T3 ES2557988 T3 ES 2557988T3
Authority
ES
Spain
Prior art keywords
active ingredients
diseases based
local supply
treat prostate
prostate diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06724133.1T
Other languages
English (en)
Spanish (es)
Inventor
Hans Lennernäs
Bo Lennernäs
Jonas Hugosson
Niklas Axen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lidds AB
Original Assignee
Lidds AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidds AB filed Critical Lidds AB
Application granted granted Critical
Publication of ES2557988T3 publication Critical patent/ES2557988T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06724133.1T 2005-03-31 2006-03-31 Método para tratar enfermedades de próstata basado en el suministro local de principios activos Expired - Lifetime ES2557988T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200500452 2005-03-31
DK200500452 2005-03-31
PCT/EP2006/003194 WO2006103112A2 (en) 2005-03-31 2006-03-31 Method for treating prostate diseases based on local delivery of active substances

Publications (1)

Publication Number Publication Date
ES2557988T3 true ES2557988T3 (es) 2016-02-01

Family

ID=35044589

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06724133.1T Expired - Lifetime ES2557988T3 (es) 2005-03-31 2006-03-31 Método para tratar enfermedades de próstata basado en el suministro local de principios activos

Country Status (17)

Country Link
US (1) US8936809B2 (cg-RX-API-DMAC10.html)
EP (1) EP1865924B1 (cg-RX-API-DMAC10.html)
JP (2) JP5635231B2 (cg-RX-API-DMAC10.html)
KR (2) KR20140014294A (cg-RX-API-DMAC10.html)
CN (1) CN101160116B (cg-RX-API-DMAC10.html)
AU (1) AU2006228675B2 (cg-RX-API-DMAC10.html)
CA (1) CA2602776C (cg-RX-API-DMAC10.html)
DK (1) DK1865924T3 (cg-RX-API-DMAC10.html)
ES (1) ES2557988T3 (cg-RX-API-DMAC10.html)
HU (1) HUE026158T2 (cg-RX-API-DMAC10.html)
IL (1) IL185690A0 (cg-RX-API-DMAC10.html)
MX (1) MX2007011908A (cg-RX-API-DMAC10.html)
NO (1) NO338679B1 (cg-RX-API-DMAC10.html)
PL (1) PL1865924T3 (cg-RX-API-DMAC10.html)
RU (1) RU2404747C2 (cg-RX-API-DMAC10.html)
WO (1) WO2006103112A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200708066B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법
MX2011005243A (es) * 2008-11-27 2011-08-08 Lidds Ab Uso de carboximetilcelulosa para controlar la eyectabilidad y el tiempo de solidificacion de las composiciones que comprenden una o mas ceramicas biorreabsorbibles.
AU2012240131B2 (en) * 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
RU2519407C2 (ru) * 2011-09-21 2014-06-10 Виктор Павлович Горелов Способ трансуретральной резекции предстательной железы, предшествующий брахитерапии рака простаты
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
GB201318862D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
WO2016028774A1 (en) 2014-08-19 2016-02-25 The Regents Of The University Of California Implants for localized drug delivery and methods of use thereof
JP6758325B2 (ja) 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
CN114767860A (zh) 2016-04-04 2022-07-22 克里蒂泰克公司 实体肿瘤治疗方法
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
AU2018284247B2 (en) 2017-06-14 2020-04-30 Crititech Inc. Methods for treating lung disorders
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
WO2020061291A1 (en) * 2018-09-20 2020-03-26 Biovena Science, Llc Flutamide microsphere-based arterial embolization for treating prostate disorders
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
US11338119B2 (en) * 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11344526B2 (en) * 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CA3171976A1 (en) * 2020-03-20 2021-09-23 Carlos Schuler Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
EP4469108A1 (en) * 2022-01-29 2024-12-04 Resurge Therapeutics, Inc. Benign prostatic hyperplasia treatment system

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
US5614206A (en) * 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
US5795330A (en) 1996-10-10 1998-08-18 Etex Corporation Mixing device
CA2268156C (en) * 1996-10-16 2007-05-29 Etex Corporation Bioceramic compositions
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US5972384A (en) * 1997-10-01 1999-10-26 University Of Maryland, Baltimore Use of biologically active glass as a drug delivery system
CA2378486A1 (en) 1999-08-05 2001-02-15 Takashi Kurasawa Osteogenesis promoter sustained-release paste
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20030147936A1 (en) * 2002-02-07 2003-08-07 Velayudhan Sahadevan Prostatic hormonal implants treatment of prostate cancer
US8404681B2 (en) * 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
GB0307082D0 (en) * 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
JP4927535B2 (ja) * 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
PL1680089T3 (pl) * 2003-10-22 2014-03-31 Lidds Ab Kompozycja zawierająca biodegradowalną ceramikę hydratującą do kontrolowanego dostarczania leków
KR20140014294A (ko) * 2005-03-31 2014-02-05 리드스 에이비 유효 물질의 국소 전달을 기본으로 하는 전립선 질병의 치료 방법

Also Published As

Publication number Publication date
EP1865924B1 (en) 2015-12-09
RU2007140243A (ru) 2009-05-10
US8936809B2 (en) 2015-01-20
JP2013067639A (ja) 2013-04-18
WO2006103112A3 (en) 2006-12-21
NO20075490L (no) 2008-01-02
AU2006228675B2 (en) 2012-05-17
KR20080002776A (ko) 2008-01-04
EP1865924A2 (en) 2007-12-19
DK1865924T3 (en) 2016-02-29
WO2006103112A2 (en) 2006-10-05
ZA200708066B (en) 2016-07-27
CN101160116A (zh) 2008-04-09
US20080286205A1 (en) 2008-11-20
NO338679B1 (no) 2016-09-26
PL1865924T3 (pl) 2016-06-30
CN101160116B (zh) 2011-12-07
JP2008534546A (ja) 2008-08-28
HUE026158T2 (en) 2016-05-30
MX2007011908A (es) 2008-02-07
CA2602776C (en) 2013-10-22
JP5635231B2 (ja) 2014-12-03
RU2404747C2 (ru) 2010-11-27
CA2602776A1 (en) 2006-10-05
KR20140014294A (ko) 2014-02-05
KR101380402B1 (ko) 2014-04-02
AU2006228675A1 (en) 2006-10-05
IL185690A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
ES2497494T3 (es) Método de tratamiento y prevención del hiperparatiroidismo secundario
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
AR047928A1 (es) Derivados de tetrahidropiridoindol
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
PA8580201A1 (es) Terapia de combinacion para enfermedades hiperproliferativas
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
GT200100152A (es) Nueva composicion farmaceutica para el tratamiento de la obesidad.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
BRPI0406796A (pt) Métodos para tratar hipertrofia prostática benigna, para reduzir um sintoma associado com a mesma, para reduzir o tamanho da próstata em um indivìduo humano e para profilaxia de bhp, composição farmacêutica oral de dose unitária, e, uso de lonidamina ou um análogo de lonidamina
NO20075490L (no) Fremgangsmate for behandling av prostatasykdommer basert pa lokal avlevering av aktive substanser
ECSP099427A (es) Barra de Tierra Segunda Generación 16 conexiones
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
MX2007000117A (es) Una composicion de combinacion.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
CU20070094A7 (es) Formas de dosificación oral sólidas que contienen una dosis baja de estradiol
ECSP099311A (es) Farmaco combinado
ATE458748T1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica